NeuroFrontiers
Clinical research and advancements furthering clinicians’ ability to diagnose and treat neurological disorders never stop. And neither does NeuroFrontiers, a series dedicated to covering them all. Here neurology specialists will find essential updates on conditions affecting the nervous system, spinal cord, and overall brain health.
So if you want to stay up to date on the latest clinical research and news on neurological disorders, then look no further. Because NeuroFrontiers is where neurology specialists and great minds explore the mind itself.
76-90 of 381
Evaluating Sabirnetug in Early Alzheimer’s: Targeting Soluble Aβ Oligomers
NeuroFrontiersEvaluating Sabirnetug in Early Alzheimer’s: Targeting Soluble Aβ Oligomers
Aducanumab in Early Alzheimer's: Slowing Cognitive and Functional Decline
NeuroFrontiersAducanumab in Early Alzheimer's: Slowing Cognitive and Functional Decline
Ryan Quigley
Optimizing Generalized Myasthenia Gravis Care Through Patient-Centered Choices
NeuroFrontiersOptimizing Generalized Myasthenia Gravis Care Through Patient-Centered Choices
Sheetal Shroff, MD
Individualizing gMG Treatment: Defining Success With Each Patient
NeuroFrontiersIndividualizing gMG Treatment: Defining Success With Each Patient
Omar Sinno, MD
Timing Meningococcal Vaccines in gMG: Challenges and Considerations
NeuroFrontiersTiming Meningococcal Vaccines in gMG: Challenges and Considerations
Michael Weiss, MD
Advancements in gMG Management: Zilucoplan as an Alternative to C5 Inhibitors
NeuroFrontiersAdvancements in gMG Management: Zilucoplan as an Alternative to C5 Inhibitors
- advertisement
Examining Inebilizumab in Generalized Myasthenia Gravis: Insights from MINT
NeuroFrontiersExamining Inebilizumab in Generalized Myasthenia Gravis: Insights from MINT
Ryan Quigley
LUMINESCE: Assessing Satralizumab in Generalized Myasthenia Gravis
NeuroFrontiersLUMINESCE: Assessing Satralizumab in Generalized Myasthenia Gravis
Understanding Antibody-Mediated Demyelinating Diseases: Key Differences From MS
NeuroFrontiersUnderstanding Antibody-Mediated Demyelinating Diseases: Key Differences From MS
Michael Levy, MD, PhD
Genetic Pathways in MS: The Clinical Impact of a Chromosome 2 Variant
NeuroFrontiersGenetic Pathways in MS: The Clinical Impact of a Chromosome 2 Variant
Sergio Baranzini, PhD
Navigating MS Diagnosis in Older Adults: Distinguishing Comorbidities and Mimics
NeuroFrontiersNavigating MS Diagnosis in Older Adults: Distinguishing Comorbidities and Mimics
Le Hua, MD
Decoding Disability Worsening in MS: The Case for Combining CSF and Serum Biomarkers
NeuroFrontiersDecoding Disability Worsening in MS: The Case for Combining CSF and Serum Biomarkers
Ryan Quigley
- advertisement
Timing Matters: Influenza Vaccination Response in MS Patients on Ofatumumab
NeuroFrontiersTiming Matters: Influenza Vaccination Response in MS Patients on Ofatumumab
Clemastine Fumarate and Progressive MS: A Closer Look at Unexpected Risks and Mechanisms
NeuroFrontiersClemastine Fumarate and Progressive MS: A Closer Look at Unexpected Risks and Mechanisms
Advances in Alzheimer’s Diagnosis: From Imaging to Artificial Intelligence
NeuroFrontiersAdvances in Alzheimer’s Diagnosis: From Imaging to Artificial Intelligence
Marc Haut, PhD
